0 341

Cited 23 times in

Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer

 Eun Jin Yoo  ;  Jun Chul Park  ;  Eun Hye Kim  ;  Chan Hyuk Park  ;  Choong Nam Shim  ;  Hyun Jik Lee  ;  Hyun Soo Chung  ;  Hyuk Lee  ;  Sung Kwan Shin  ;  Sang Kil Lee  ;  Chang Geol Lee  ;  Yong Chan Lee 
 DIGESTIVE AND LIVER DISEASE, Vol.46(9) : 846-853, 2014 
Journal Title
Issue Date
Aged ; Antineoplastic Agents/therapeutic use* ; Chemoradiotherapy ; Disease-Free Survival ; Esophageal Neoplasms/blood ; Esophageal Neoplasms/mortality ; Esophageal Neoplasms/therapy* ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphocytes/pathology* ; Male ; Neoplasm Staging* ; Neutrophils/pathology* ; Prognosis ; Republic of Korea/epidemiology ; Retrospective Studies ; Survival Rate
Concurrent chemoradiotherapy ; Neutrophil-to-lymphocyte ratio ; Oesophageal cancer ; Prognosis
BACKGROUND: We performed a retrospective analysis of Asian patients with locally advanced oesophageal cancer to test the hypothesis that an elevated neutrophil-to-lymphocyte ratio is associated with a poor survival rate after definitive concurrent chemoradiotherapy. METHODS: In total, 138 patients diagnosed with locally advanced oesophageal cancer (TNM classification of malignant tumours stage II or III) who were treated with definitive concurrent chemoradiotherapy between January 2005 and December 2010 were retrospectively analysed. Definitive concurrent chemoradiotherapy was performed using two different chemotherapy regimens. RESULTS: The median follow-up duration was 39.5 months (range 1.1-93.4). The median progression-free survival was 14.0 months, and the median overall survival was 19.9 months. Compared with the low (<2.0) neutrophil-to-lymphocyte ratio group (n=43, 31.2%), the high (≥2.0) neutrophil-to-lymphocyte ratio group (n=95, 68.8%) exhibited significant decreases in the durations of both progression-free survival and overall survival. Using multivariate analysis, an elevated neutrophil-to-lymphocyte ratio was also significantly associated with decreased progression-free survival (HR 1.799; 95% CI, 1.050-3.083; P=0.032) and overall survival duration (HR 2.115; 95% CI, 1.193-3.749; P=0.010). CONCLUSIONS: The pretreatment neutrophil-to-lymphocyte ratio is a useful prognostic marker in patients with locally advanced oesophageal cancer treated with definitive concurrent chemoradiotherapy.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Eun Hye(김은혜) ORCID logo https://orcid.org/0000-0001-6691-6837
Park, Jun Chul(박준철) ORCID logo https://orcid.org/0000-0001-8018-0010
Park, Chan Hyuk(박찬혁)
Shin, Sung Kwan(신성관) ORCID logo https://orcid.org/0000-0001-5466-1400
Shim, Choong Nam(심충남)
Yoo, Eun Jin(유은진)
Lee, Sang Kil(이상길) ORCID logo https://orcid.org/0000-0002-0721-0364
Lee, Yong Chan(이용찬) ORCID logo https://orcid.org/0000-0001-8800-6906
Lee, Chang Geol(이창걸) ORCID logo https://orcid.org/0000-0002-8702-881X
Lee, Hyuk(이혁)
Lee, Hyun Jik(이현직)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.